Trial Profile
A randomized, double-blinded, placebo controlled, parallel group, multi-center study to assess safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of intravenous doses of QAX576 in moderate persistent allergic asthmatics following inhaled corticosteroid withdrawal
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Dectrekumab (Primary)
- Indications Allergic asthma
- Focus Biomarker; Therapeutic Use
- 20 May 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 02 Feb 2008 New trial record.